Abstract
Background BCL6 was a critical prooncogene of human B-cell lymphomas which promoted tumor progress and contributed to malignant behavior in several kinds of cancers. This study was to detect the expression of BCL6 and its biological effect on glioma. Methods RT-PCR and Western blot were used to detect the expression of BCL6 mRNA and protein in tissues and glioblastoma cell lines. The expression of BCL6 was knockdown in two glioblastoma cell lines (U87 and U251) using BCL6 shRNA. The CCK8, colony-formation, flow cytometry, Transwell, and wound-healing assays were used to evaluate the malignant phenotypic change of glioblastoma cells. Results The expression of BCL6 was higher in glioma tissues and glioblastoma cell lines than normal tissues. Knockdown of BCL6 expression reduced the proliferation, migration, and invasion of glioblastoma cells. Moreover, knockdown of BCL6 changed expression of proteins related to malignant behaviors of glioblastoma cells. The suppression of BCL6 could increase chemosensitivity of U87 and U251 to temozolomide. Downregulation of BCL6 levels suppressed the expression of BCL2, cyclin D1, MMP2, and MMP9 proteins as well as two classic signaling pathway proteins p-AKT and p-ERK. Simultaneously, BAX and p21 protein levels were upregulated along with knockdown of BCL6. Conclusions Our results indicated that BCL6 may be a tumor oncogene involved in the progression of glioma via affecting AKT and MAPK signaling pathways.
Highlights
Glioblastoma (GBM) is the most aggressive and lethal brain malignancy which is commonly referred to grade IV astrocytoma classified by World Health Organization (WHO)
We identified the high expression of B-cell lymphoma 6 (BCL6) in glioma tissues and cell lines, and we investigated the role of BCL6 expression in regulation of glioblastoma proliferation, migration, invasion, and chemosensitivity in vitro
The glioma tissues showed a higher level of BCL6 protein than the normal brain tissues (Figure 1(c))
Summary
Glioblastoma (GBM) is the most aggressive and lethal brain malignancy which is commonly referred to grade IV astrocytoma classified by World Health Organization (WHO). B-cell lymphoma 6 (BCL6), one of zinc finger transcriptional factor, works as a critical regulator in germinal center response. This gene is a key prooncogene of human B-cell lymphomas which participants in regulating the cell proliferation, differentiation and apoptosis of B and T cells [4]. BCL6 was a critical prooncogene of human B-cell lymphomas which promoted tumor progress and contributed to malignant behavior in several kinds of cancers. Knockdown of BCL6 expression reduced the proliferation, migration, and invasion of glioblastoma cells. Knockdown of BCL6 changed expression of proteins related to malignant behaviors of glioblastoma cells. Our results indicated that BCL6 may be a tumor oncogene involved in the progression of glioma via affecting AKT and MAPK signaling pathways
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call